Role of C-terminal negative charges and tyrosine residues in fibril formation of α-synuclein

Brain and Behavior

Volumn 2, Issue 5, 2012, Pages 595-605

  Izawa, Yasutaka ^a   Tateno, Hironobu ^a   Kameda, Hiroshi ^b   Hirakawa, Kazuya ^b   Hato, Keiko ^a   Yagi, Hisashi ^a   Hongo, Kunihiro ^a,b   Mizobata, Tomohiro ^a,b   Kawata, Yasushi ^a,b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Synuclein; Amyloid; Amyloid formation mechanism; Parkinson's disease; Protein aggregation; Site directed mutagenesis

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; AMINO ACID; AMYLOID; TYROSINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONTROLLED STUDY; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

EID: 84893441655     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.86     Document Type: Article

References (40)

1. Baba, M., S. Nakajo, P. H. Tu, T. Tomita, K. Nakaya, V. M. Lee, et al. 1998. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:879-884.
2. Bisaglia, M., S. Mammi, and L. Bubacco 2009. Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J. 23:329-340.
3. Carrell, R. W., and D. A. Lomas 1997. Conformational disease. Lancet 350:134-138.
4. Cho, M. K., G. Nodet, H. Y. Kim, M. R. Jensen, P. Bernado, C. O. Fernandez, et al. 2009. Structural characterization of alpha-synuclein in an aggregation prone state. Protein Sci. 18:1840-1846.
5. Conway, K. A., J. D. Harper, and P. T. Lansbury Jr. 2000. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39:2552-2563.
6. Crowther, R. A., R. Jakes, M. G. Spillantini, and M. Goedert 1998. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436:309-312.
7. Goedert, M. 2001. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2:492-501.
8. Heise, H., W. Hoyer, S. Becker, O. C. Andronesi, D. Riedel, and M. Baldus 2005. Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc. Natl. Acad. Sci. USA 102:15871-15876.
9. Higurashi, T., H. Yagi, T. Mizobata, and Y. Kawata 2005. Amyloid-like fibril formation of co-chaperonin GroES: nucleation and extension prefer different degrees of molecular compactness. J. Mol. Biol. 351:1057-1069.
10. Horvath, I., C. F. Weise, E. K. Andersson, E. Chorell, M. Sellstedt, C. Bengtsson, et al. 2012. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation. J. Am. Chem. Soc. 134:3439-3444.
11. Hoyer, W., D. Cherny, V. Subramaniam, and T. M. Jovin 2004. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43:16233-16242.
12. Iwai, A., E. Masliah, M. Yoshimoto, N. Ge, L. Flanagan, H. A. de Silva, et al. 1995. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475.
13. Levitan, K., D. Chereau, S. I. Cohen, T. P. Knowles, C. M. Dobson, A. L. Fink, et al. 2011. Conserved C-terminal charge exerts a profound influence on the aggregation rate of alpha-synuclein. J. Mol. Biol. 411:329-333.
14. Levy, M., N. Garmy, E. Gazit, and J. Fantini 2006. The minimal amyloid-forming fragment of the islet amyloid polypeptide is a glycolipid-binding domain. FEBS J. 273:5724-5735.
15. Li, J., V. N. Uversky, and A. L. Fink 2002. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23:553-567.
16. Li, W., N. West, E. Colla, O. Pletnikova, J. C. Troncoso, L. Marsh, et al. 2005. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. USA 102:2162-2167.
17. Liu, C. W., B. I. Giasson, K. A. Lewis, V. M. Lee, G. N. Demartino, and P. J. Thomas 2005. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280:22670-22678.
18. Makin, O. S., E. Atkins, P. Sikorski, J. Johansson, and L. C. Serpell 2005. Molecular basis for amyloid fibril formation and stability. Proc. Natl. Acad. Sci. USA 102:315-320.
19. McClendon, S., C. C. Rospigliosi, and D. Eliezer 2009. Charge neutralization and collapse of the C-terminal tail of alpha-synuclein at low pH. Protein Sci. 18:1531-1540.
20. Murray, I. V., B. I. Giasson, S. M. Quinn, V. Koppaka, P. H. Axelsen, H. Ischiropoulos, et al. 2003. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42:8530-8540.
21. Nakajo, S., S. Shioda, Y. Nakai, and K. Nakaya 1994. Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Brain Res. Mol. Brain Res. 27:81-86.
22. Narhi, L., S. J. Wood, S. Steavenson, Y. Jiang, G. M. Wu, D. Anafi, et al. 1999. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274:9843-9846.
23. Norris, E. H., B. I. Giasson, and V. M. Lee 2004. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 60:17-54.
24. Pace, C. N., F. Vajdos, L. Fee, G. Grimsley, and T. Gray 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4:2411-2423.
25. Selkoe, D. J. 2003. Folding proteins in fatal ways. Nature 426:900-904.
26. Serpell, L. C., J. Berriman, R. Jakes, M. Goedert, and R. A. Crowther 2000. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA 97:4897-4902.
27. Shastry, B. S. 2003. Neurodegenerative disorders of protein aggregation. Neurochem. Int. 43:1-7.
28. Sipe, J. D., and A. S. Cohen 2000. Review: history of the amyloid fibril. J. Struct. Biol. 130:88-98.
29. Spillantini, M. G., M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
30. Sunde, M., and C. Blake 1997. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem. 50:123-159.
31. Tan, S. Y., and M. B. Pepys 1994. Amyloidosis. Histopathology 25:403-414.
32. Ueda, K., H. Fukushima, E. Masliah, Y. Xia, A. Iwai, M. Yoshimoto, et al. 1993. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:11282-11286.
33. Ulrih, N. P., C. H. Barry, and A. L. Fink 2008. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Biochim. Biophys. Acta 1782:581-585.
34. Uversky, V. N., J. Li, and A. L. Fink 2001. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276:10737-10744.
35. Weinreb, P. H., W. Zhen, A. W. Poon, K. A. Conway, and P. T. Lansbury Jr. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35:13709-13715.
36. Wu, K. P., D. S. Weinstock, C. Narayanan, R. M. Levy, and J. Baum 2009. Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations. J. Mol. Biol. 391:784-796.
37. Yagi, H., E. Kusaka, K. Hongo, T. Mizobata, and Y. Kawata 2005. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases. J. Biol. Chem. 280:38609-38616.
38. Yagi, H., A. Sato, A. Yoshida, Y. Hattori, M. Hara, J. Shimamura, et al. 2008. Fibril formation of hsp10 homologue proteins and determination of fibril core regions: differences in fibril core regions dependent on subtle differences in amino acid sequence. J. Mol. Biol. 377:1593-1606.
39. Yagi, H., H. Takeuchi, S. Ogawa, N. Ito, I. Sakane, K. Hongo, et al. 2010. Isolation of short peptide fragments from alpha-synuclein fibril core identifies a residue important for fibril nucleation: a possible implication for diagnostic applications. Biochim. Biophys. Acta 1804:2077-2087.
40. Yamin, G., V. N. Uversky, and A. L. Fink 2003. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542:147-152.